[go: up one dir, main page]

NO2024009I1 - Gefapixant, or a pharmaceutically acceptable salt thereof - Google Patents

Gefapixant, or a pharmaceutically acceptable salt thereof

Info

Publication number
NO2024009I1
NO2024009I1 NO2024009C NO2024009C NO2024009I1 NO 2024009 I1 NO2024009 I1 NO 2024009I1 NO 2024009 C NO2024009 C NO 2024009C NO 2024009 C NO2024009 C NO 2024009C NO 2024009 I1 NO2024009 I1 NO 2024009I1
Authority
NO
Norway
Prior art keywords
gefapixant
pharmaceutically acceptable
acceptable salt
salt
pharmaceutically
Prior art date
Application number
NO2024009C
Other languages
English (en)
Original Assignee
Afferent Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Afferent Pharmaceuticals Inc filed Critical Afferent Pharmaceuticals Inc
Publication of NO2024009I1 publication Critical patent/NO2024009I1/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/06Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/14Antitussive agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Dispersion Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO2024009C 2015-09-29 2024-03-06 Gefapixant, or a pharmaceutically acceptable salt thereof NO2024009I1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562234584P 2015-09-29 2015-09-29
US201662336381P 2016-05-13 2016-05-13

Publications (1)

Publication Number Publication Date
NO2024009I1 true NO2024009I1 (no) 2024-03-06

Family

ID=58424436

Family Applications (1)

Application Number Title Priority Date Filing Date
NO2024009C NO2024009I1 (no) 2015-09-29 2024-03-06 Gefapixant, or a pharmaceutically acceptable salt thereof

Country Status (22)

Country Link
US (3) US11260056B2 (no)
EP (2) EP3355889B1 (no)
JP (1) JP6877441B2 (no)
KR (1) KR20180054843A (no)
AU (1) AU2016330466B2 (no)
CA (1) CA2998742C (no)
CY (2) CY1125963T1 (no)
DK (1) DK3355889T3 (no)
ES (1) ES2942711T3 (no)
FI (2) FI3355889T3 (no)
FR (1) FR24C1010I2 (no)
HR (1) HRP20230445T1 (no)
HU (2) HUE061764T2 (no)
LT (1) LT3355889T (no)
MX (1) MX390084B (no)
NL (1) NL301260I2 (no)
NO (1) NO2024009I1 (no)
PL (1) PL3355889T3 (no)
PT (1) PT3355889T (no)
RS (1) RS64155B1 (no)
SI (1) SI3355889T1 (no)
WO (1) WO2017058645A1 (no)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220148928A (ko) 2016-12-20 2022-11-07 애퍼런트 파마슈티컬스 인크. P2x3 길항제의 결정질 염 및 다형체
US10111883B1 (en) * 2017-09-18 2018-10-30 Bellus Health Cough Inc. Selective P2X3 modulators
KR20210009341A (ko) * 2018-05-15 2021-01-26 바이엘 악티엔게젤샤프트 신경 섬유 감작과 연관된 질환의 치료를 위한 1,3-티아졸-2-일 치환된 벤즈아미드
US11883407B2 (en) * 2018-10-05 2024-01-30 Shionogi & Co., Ltd. Medicament for the treatment of chronic cough
CA3138780A1 (en) * 2019-04-30 2020-11-05 Beijing Tide Pharmaceutical Co., Ltd. Method for treating cough by using diaminopyrimidine compound
AU2020281923A1 (en) 2019-05-31 2022-01-06 Chiesi Farmaceutici S.P.A. Amino quinazoline derivatives as P2X3 inhibitors
JP2022534434A (ja) 2019-05-31 2022-07-29 キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ P2x3阻害剤としてのピリドピリミジン誘導体
EP4032884A4 (en) 2019-09-19 2023-09-13 Shionogi & Co., Ltd. 1,3,5-TRIAZINE DERIVATIVE CRYSTAL OR SOLVATE THEREOF AND PRODUCTION METHOD THEREFOR
CN111635368B (zh) * 2020-06-12 2021-06-29 东莞市东阳光仿制药研发有限公司 一种胺化合物的制备方法
MX2023005805A (es) 2020-11-27 2023-06-01 Chiesi Farm Spa Derivados de 4-aminas de (aza)quinolina como inhibidores del purinorreceptor 3 p2x (p2x3).
JP2023550831A (ja) 2020-11-27 2023-12-05 キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ P2x3阻害剤としてのフタラジン誘導体
KR20230113309A (ko) 2020-11-27 2023-07-28 키에시 파르마슈티시 엣스. 피. 에이. P2x3 억제제로서 아미노 퀴나졸린 유도체

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1725540T3 (pl) 2004-03-05 2013-02-28 Hoffmann La Roche Diaminopirymidyny jako antagoniści p2x3 i p2x2/3
EP1773405A4 (en) 2004-07-22 2011-10-05 Duska Scient Co METHOD FOR DIAGNOSIS, MONITORING AND TREATMENT OF LUNG DISEASES
WO2007025899A1 (en) 2005-09-01 2007-03-08 F. Hoffmann-La Roche Ag Diaminopyrimidines as p2x3 and p2x2/3 modulators
ES2562056T3 (es) 2005-09-01 2016-03-02 F. Hoffmann-La Roche Ag Diaminopirimidinas como moduladores P2X3 y P2X2/3
JP4850914B2 (ja) * 2005-09-01 2012-01-11 エフ.ホフマン−ラ ロシュ アーゲー P2x3およびp2x2/3モジュレーターとしてのジアミノピリミジン
JP4820873B2 (ja) 2005-09-01 2011-11-24 エフ.ホフマン−ラ ロシュ アーゲー アリールオキシジアミノピリミジンの合成方法
KR101176701B1 (ko) * 2006-10-04 2012-08-23 에프. 호프만-라 로슈 아게 펜옥시 다이아미노피리미딘 유도체의 합성 방법
WO2008104474A1 (en) * 2007-02-28 2008-09-04 F. Hoffmann-La Roche Ag Diaminopyrimidines
US9284279B2 (en) * 2013-08-23 2016-03-15 Afferent Pharmaceuticals, Inc. Substituted pyrimidines for treatment of acute cough, chronic cough and urge to cough

Also Published As

Publication number Publication date
HUS2400004I1 (hu) 2024-04-28
RS64155B1 (sr) 2023-05-31
MX2018003893A (es) 2018-06-22
FR24C1010I1 (fr) 2024-05-24
AU2016330466A1 (en) 2018-03-29
HRP20230445T1 (hr) 2023-07-21
US11260056B2 (en) 2022-03-01
DK3355889T3 (da) 2023-05-15
EP3355889A1 (en) 2018-08-08
CA2998742A1 (en) 2017-04-06
CY1125963T1 (el) 2024-09-20
LT3355889T (lt) 2023-05-10
ES2942711T3 (es) 2023-06-06
CY2024005I2 (el) 2024-09-20
PL3355889T3 (pl) 2023-05-22
CA2998742C (en) 2023-08-29
JP6877441B2 (ja) 2021-05-26
CY2024005I1 (el) 2024-09-20
US20220143015A1 (en) 2022-05-12
EP4215182A1 (en) 2023-07-26
AU2016330466B2 (en) 2021-01-28
FR24C1010I2 (fr) 2024-12-13
JP2018529776A (ja) 2018-10-11
EP3355889B1 (en) 2023-02-15
WO2017058645A1 (en) 2017-04-06
US20180280388A1 (en) 2018-10-04
NL301260I2 (nl) 2024-03-25
SI3355889T1 (sl) 2023-07-31
KR20180054843A (ko) 2018-05-24
FIC20240006I1 (fi) 2024-03-13
PT3355889T (pt) 2023-04-26
US20240285620A1 (en) 2024-08-29
MX390084B (es) 2025-03-20
HUE061764T2 (hu) 2023-08-28
EP3355889A4 (en) 2019-05-22
FI3355889T3 (fi) 2023-05-15

Similar Documents

Publication Publication Date Title
NO2021035I1 (no) Risdiplam or a pharmaceutically acceptable salt thereof
NL301286I2 (nl) Danicopan, of een farmaceutisch aanvaardbaar zout ervan
NO2024001I1 (no) Ritlecitinib, or a pharmaceutically acceptable salt thereof
NO2022059I1 (no) Lenacapavir or a pharmaceutically acceptable salt thereof, in particular lenacapavir sodium
NO2022004I1 (no) abrocitinib, or a pharmaceutically acceptable salt thereof
NO2024042I1 (no) Iptacopan or a pharmaceutically acceptable salt thereof
NO2023043I1 (no) Mavacamten or a pharmaceutically acceptable salt thereof
NL301111I2 (nl) Entrectinib of een farmaceutisch aanvaardbaar zout daarvan
NO2022005I1 (no) Zanubrutinib or a pharmaceutically acceptable salt thereof
NO2024009I1 (no) Gefapixant, or a pharmaceutically acceptable salt thereof
NO2022009I1 (no) Lumasiran, optionally in the form of a salt
NL301217I2 (nl) tirzepatide en farmaceutisch aanvaardbare zouten daarvan
NO2024007I1 (no) Elacestrant or a salt thereof
NO2022058I1 (no) Capmatinib or a pharmaceutically acceptable salt thereof
FIC20240025I1 (fi) Momelotinibi, mukaanlukien momelotinibidihydrokloridimonohydraatti
LT3230281T (lt) 1,3-tiazol-2-ilu pakeisti benzamidai
LT3188717T (lt) Vaisto forma, apimanti daleles
DK3253762T3 (da) 9h-pyrrolo-dipyridinderivater.
BR112017027227A2 (pt) Agente anti-câncer
IL255823A (en) Urea derivative or pharmacologically acceptable salt thereof
BR112017014839A2 (pt) novos microbicidas
LT3371168T (lt) Indolin-2-ono dariniai
DK3445742T3 (da) Krystallin tapentadolphosphat
NO2024058I1 (no) delgocitinib or a pharmaceutically acceptable salt thereof
ZA201708611B (en) Pyrazole derivative, or pharmaceutically acceptable salt thereof